Investigational drug · Phase 3
MLC1501
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Stroke, Stroke, Ischemic, Strokes Thrombotic.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "MLC1501"
First trial start
2023
Jul 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MLC1501", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stroke
- Stroke, Ischemic
- Strokes Thrombotic
- Stroke Sequelae
- Stroke, Cardiovascular
- Stroke, Embolic
- Stroke, Cryptogenic
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MLC1501" as an intervention, largest first.
- MLC1501 Study Assessing Efficacy in STROke RecoveryPivotal-lookingNot yet recruiting
Moleac Pte Ltd.Industry
NCT05046106 · 540 participants (planned) · Start Jan 2025 · Primary completion Sep 2028
Drug: MLC1501 · For: Stroke; Stroke, Ischemic; Strokes Thrombotic and 4 more
- MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor DeficitsPivotal-lookingCompleted
Moleac Pte Ltd.Industry
NCT05289947 · 303 participants · Start Jul 21, 2023 · Primary completion Jul 18, 2025
Drug: MLC1501 · For: Stroke; Stroke, Ischemic; Strokes Thrombotic and 4 more
Sites: Davao City, Philippines; Manila, Philippines; Baguio City, Philippines · 11 sites in all
Moleac Pte Ltd.Industry
NCT04233437 · 27 participants · Start Feb 10, 2020 · Primary completion May 16, 2020
Drug: MLC1501; CYP Cocktail and 1 more · For: Stroke
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Phase II randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of MLC1501 in patients with stroke: the MLC1501 study Assessing Efficacy in post-STrOke Subjects with mOtor deficits (MAESTOSO) study protocol.
Chen CPLH, Esagunde RU, Escabillas CG, et al. · Stroke Vasc Neurol 2025
Also in development for Stroke
- AbelacimabMAA868Phase 33 trials
Anthos Therapeutics, Inc. · Atrial Fibrillation (AF), Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.